Abstract
Vascular Endothelial Growth Factor-A (VEGF-A) is one of the most important regulators of physiological and pathological angiogenesis. Constitutive activation of the ERK pathway and over-expression of VEGF-A are common denominators of tumours of different origins. Understanding VEGF-A regulation is of primary importance to better comprehend pathological angiogenesis. VEGF-A expression is regulated at all steps of its synthesis including transcription, mRNA stability, an under estimated way of VEGF regulation and translation. In this chapter, we present the link between VEGF mRNA stability through AU-rich sequences present in its 3′-untranslated region (3′-UTR) and the ERK pathway. We present several methods that have been used to demonstrate that ERKs increase VEGF mRNA half-life. This mRNA-stabilising effect is partly due to reduction of the mRNA destabilising effects of Tristetraprolin (TTP), an AU-Rich binding protein which binds to VEGF-A mRNA 3′-UTR.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Folkman, J., and Shing, Y. (1992) Angiogenesis. J Biol Chem 267, 10931–4.
Folkman, J., and D’Amore, P. A. (1996) Blood vessel formation: what is its molecular basis? Cell 87, 1153–5.
Mukhopadhyay, D., Tsiokas, L., Zhou, X. M., Foster, D., Brugge, J. S., and Sukhatme, V. P. (1995) Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375, 577–581.
Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H. R., and Folkman, J. (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 94, 861–6.
Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151, 1523–30.
Akagi, Y., Liu, W., Zebrowski, B., Xie, K., and Ellis, L. M. (1998) Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58, 4008–14.
Ellis, L. M., Staley, C. A., Liu, W., Fleming, R. Y., Parikh, N. U., Bucana, C. D., and Gallick, G. E. (1998) Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273, 1052–7.
Yen, L., You, X. L., Al Moustafa, A. E., Batist, G., Hynes, N. E., Mader, S., Meloche, S., and Alaoui-Jamali, M. A. (2000) Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19, 3460–9.
Milanini, J., Vinals, F., Pouysségur, J., and Pagès, G. (1998) p42/p44 MAP Kinase module plays a key role in the transcriptional regulation of vascular endothelial growth factor gene in fibroblasts. J Biol Chem 273, 18165–72.
Rak, J., Mitsuhashi, Y., Sheehan, C., Tamir, A., Vioria-Petit, A., Filmus, J., Mansour, S. J., Ahn, N. G., and Kerbel, R. S. (2000) Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras transformed epithelial cells and fibroblasts. Cancer Res 60, 490–498.
Pagès, G., Milanini, J., Richard, D. E., Berra, E., Gothie, E., Vinals, F., and Pouysségur, J. (2000) Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci 902, 187–200.
Marchetti, S., Gimond, C., Roux, D., Gothie, E., Pouysségur, J., and Pagès, G. (2004) Inducible expression of a MAP kinase phosphatase-3-GFP chimera specifically blunts fibroblast growth and ras-dependent tumor formation in nude mice. J Cell Physiol 199, 441–50.
Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E., Thomas, D., Koller, C., Estrov, Z., O’Brien, S., Keating, M., Freireich, E., and Albitar, M. (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96, 2240–5.
Legros, L., Bourcier, C., Jacquel, A., Mahon, F. X., Cassuto, J. P., Auberger, P., and Pagès, G. (2004) Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 104, 495–501.
Strowski, M. Z., Cramer, T., Schafer, G., Juttner, S., Walduck, A., Schipani, E., Kemmner, W., Wessler, S., Wunder, C., Weber, M., Meyer, T. F., Wiedenmann, B., Jons, T., Naumann, M., and Hocker, M. (2004) Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. FASEB J 18, 218–20.
Milanini-Mongiat, J., Pouyssegur, J., and Pagès, G. (2002) Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 277, 20631–9.
Pagès, G. (2007) Sp3-Mediated VEGF regulation is dependent on phosphorylation by extra-cellular signals regulated kinases (Erk). J Cell Physiol 213, 454–63.
Abdelrahim, M., Smith, R., 3rd, Burghardt, R., and Safe, S. (2004) Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64, 6740–9.
Abdelrahim, M., Baker, C. H., Abbruzzese, J. L., and Safe, S. (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98, 855–68.
Essafi-Benkhadir, K., Grosso, S., Puissant, A., Robert, G., Essafi, M., Deckert, M., Chamorey, E., Dassonville, O., Milano, G., Auberger, P., and Pagès, G. (2009) Dual role of Sp3 transcription factor as an inducer of apoptosis and a marker of tumour aggressiveness. PLoS One 4, e4478.
Mylonis, I., Chachami, G., Samiotaki, M., Panayotou, G., Paraskeva, E., Kalousi, A., Georgatsou, E., Bonanou, S., and Simos, G. (2006) Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 281, 33095–106.
Richard, D. E., Berra, E., Gothie, E., Roux, D., and Pouysségur, J. (1999) p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274, 32631–7.
Andoh, A., Shimada, M., Bamba, S., Okuno, T., Araki, Y., Fujiyama, Y., and Bamba, T. (2002) Extracellular signal-regulated kinases 1 and 2 participate in interleukin-17 plus tumor necrosis factor-alpha-induced stabilization of interleukin-6 mRNA in human pancreatic myofibroblasts. Biochim Biophys Acta 1591, 69–74.
Levy, N. S., Chung, S., Furneaux, H., and Levy, A. P. (1998) Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273, 6417–23.
Shih, S. C., and Claffey, K. P. (1999) Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem 274, 1359–65.
Onesto, C., Berra, E., Grépin, R., and Pagès, G. (2004) Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J Biol Chem 279, 34217–26.
Ciais, D., Cherradi, N., Bailly, S., Grenier, E., Berra, E., Pouysségur, J., Lamarre, J., and Feige, J. J. (2004) Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b. Oncogene 23, 8673–80.
Essafi-Benkhadir, K., Onesto, C., Stebe, E., Moroni, C., and Pagès, G. (2007) Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. Mol Biol Cell 18, 4648–58.
Cao, H., Deterding, L. J., Venable, J. D., Kennington, E. A., Yates, J. R., 3rd, Tomer, K. B., and Blackshear, P. J. (2006) Identification of the anti-inflammatory protein tristetraprolin as a hyperphosphorylated protein by mass spectrometry and site-directed mutagenesis. Biochem J 394, 285–97.
Doller, A., Huwiler, A., Muller, R., Radeke, H. H., Pfeilschifter, J., and Eberhardt, W. (2007) Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. Mol Biol Cell 18, 2137–48.
Doller, A., Akool el, S., Huwiler, A., Muller, R., Radeke, H. H., Pfeilschifter, J., and Eberhardt, W. (2008) Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol 28, 2608–25.
Stoecklin, G., Gross, B., Ming, X. F., and Moroni, C. (2003) A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene 22, 3554–61.
Levy, A. P., Levy, N. S., and Goldberg, M. A. (1996) Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271, 2746–53.
Lenormand, P., McMahon, M., and Pouysségur, J. (1996) Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway. J Biol Chem 271, 15762–8.
Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3, 1101–8.
Cagnol, S., Van Obberghen-Schilling, E., and Chambard, J. C. (2006) Prolonged activation of ERK1,2 induces FADD-independent caspase 8 activation and cell death. Apoptosis 11, 337–46.
Niranjanakumari, S., Lasda, E., Brazas, R., and Garcia-Blanco, M. A. (2002) Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo. Methods 26, 182–90.
Thavathiru, E., and Das, G. M. (2001) Activation of pRL-TK by 12S E1A oncoprotein: drawbacks of using an internal reference reporter in transcription assays. Biotechniques 31, 528–30, 532.
Matuszyk, J., Ziolo, E., Cebrat, M., Kochel, I., and Strzadala, L. (2002) Nurr1 affects pRL-TK but not phRG-B internal control plasmid in genetic reporter system. Biochem Biophys Res Commun 294, 1036–9.
Sims, R. J., 3rd, Liss, A. S., and Gottlieb, P. D. (2003) Normalization of luciferase reporter assays under conditions that alter internal controls. Biotechniques 34, 938–40.
Mulholland, D. J., Cox, M., Read, J., Rennie, P., and Nelson, C. (2004) Androgen responsiveness of Renilla luciferase reporter vectors is promoter, transgene, and cell line dependent. Prostate 59, 115–9.
Ho, C. K., and Strauss, J. F., 3rd. (2004) Activation of the control reporter plasmids pRL-TK and pRL-SV40 by multiple GATA transcription factors can lead to aberrant normalization of transfection efficiency. BMC Biotechnol 4, 10.
Acknowledgements
This work was supported by the French association for cancer research (ARC, 4932), by the Association for International Cancer Research (AICR) and the French National Institute of Cancer (INCa).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Meida, LLC
About this protocol
Cite this protocol
Essafi-Benkhadir, K., Pouysségur, J., Pagès, G. (2010). Implication of the ERK Pathway on the Post-transcriptional Regulation of VEGF mRNA Stability. In: Seger, R. (eds) MAP Kinase Signaling Protocols. Methods in Molecular Biology, vol 661. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-795-2_28
Download citation
DOI: https://doi.org/10.1007/978-1-60761-795-2_28
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-794-5
Online ISBN: 978-1-60761-795-2
eBook Packages: Springer Protocols